BMND — Biomind Labs Share Price
Last trade - 00:00- CA$27.54m
- CA$28.71m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Biomind Labs Inc. developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders. The Company is focused transforming biomedical sciences knowledge into fast-acting and controlled-release novel drugs. Its product pipelines incudes BMND01 (Treatment-Resistant Depression), BMND02 (Fibromyalgia), BMND03 (Addictive Disorders), BMND05 (Chronic Pain), BMND06 (Morbid Obesity), BMND07 (Major Depressive Disorder), BMND08 (Alzheimer's), and BMND09 (Parkinson's Disease).
Directors
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- July 15th, 2021
- Public Since
- July 27th, 2021
- No. of Employees
- 2
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Canadian Securities Exchange
- Shares in Issue
- 77,571,773
- Address
- VANCOUVER, V7Y 1C6
- Web
- https://www.biomindlabs.com
- Phone
- Auditors
- Davidson & Company LLP
Similar to BMND
Albert Labs International
Canadian Securities Exchange
Asep Medical Holdings
Canadian Securities Exchange
BetterLife Pharma
Canadian Securities Exchange
BioMark Diagnostics
Canadian Securities Exchange
Biovaxys Technology
Canadian Securities Exchange
FAQ
As of Today at 01:37 UTC, shares in Biomind Labs are trading at CA$0.36. This share price information is delayed by 15 minutes.
Shares in Biomind Labs last closed at CA$0.36 and the price had moved by +1.43% over the past 365 days. In terms of relative price strength the Biomind Labs share price has underperformed the Toronto Stock Exchange 300 Composite Index by -14.51% over the past year.
There is no consensus recommendation for this security.
Find out moreBiomind Labs does not currently pay a dividend.
Biomind Labs does not currently pay a dividend.
Biomind Labs does not currently pay a dividend.
To buy shares in Biomind Labs you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.36, shares in Biomind Labs had a market capitalisation of CA$27.54m.
Here are the trading details for Biomind Labs:
- Country of listing: Canada
- Exchange: CNX
- Ticker Symbol: BMND
Based on an overall assessment of its quality, value and momentum Biomind Labs is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biomind Labs. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +53.43%.
As of the last closing price of CA$0.36, shares in Biomind Labs were trading -8.3% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Biomind Labs PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.36.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Biomind Labs' management team is headed by:
- Trumbull Fisher - CEO
- Arvin Ramos - CFO
- Daniel Nauth - DRC
- Jessica Whitton - DRC